US 12,115,214 B2
Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif
Rikard Holmdahl, Lund (SE); Jan Kihlberg, Pixbo (SE); Balik Dzhambazov, Plovdiv (BG); and Mikael Vestberg, Södra Sandby (SE)
Assigned to Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V., Munich (DE)
Filed by Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V, Munich (DE)
Filed on Nov. 15, 2019, as Appl. No. 16/685,424.
Application 16/685,424 is a division of application No. 14/658,962, filed on Mar. 16, 2015, granted, now 10,588,951.
Application 14/658,962 is a continuation of application No. 12/092,724, abandoned, previously published as PCT/SE2006/001290, filed on Nov. 15, 2006.
Claims priority of provisional application 60/758,481, filed on Jan. 12, 2006.
Claims priority of application No. 0502530-9 (SE), filed on Nov. 17, 2005.
Prior Publication US 2020/0085927 A1, Mar. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 16/18 (2006.01)
CPC A61K 39/0008 (2013.01) [A61K 47/6425 (2017.08); A61K 47/6811 (2017.08); A61K 47/6843 (2017.08); C07K 7/08 (2013.01); C07K 14/4713 (2013.01); C07K 14/705 (2013.01); C07K 16/18 (2013.01); A61K 2039/605 (2013.01); A61K 2039/6056 (2013.01); C07K 2319/33 (2013.01)] 14 Claims
 
1. A method of treatment of rheumatoid arthritis comprising administering to a patient a pharmaceutically effective dose of a compound comprising (a) a peptide and (b) a carrier, wherein said peptide is bound within the peptide-binding site of said carrier, and
a. said peptide consists of a peptide of 12 to 20 amino acid residues and comprises at least a motif consisting of IAGFKGEQGPKG (SEQ ID NO: 7), wherein at least the lysine at position 5 of said motif is a glycosylated hydroxylysine and
b. said carrier comprises at least the variable region of a naturally occurring MHC class II molecule wherein said carrier does not comprise a transmembrane domain and cytoplasmic domain of the alpha and beta chains of said naturally occurring MHC class II molecule and said alpha and beta chains are linked to each other by a leucine zipper or an immunoglobulin, and
wherein said carrier comprises the variable region of an MHC class II molecule of DRB1*0401/DRA.